LGM
Logos Global Management Portfolio holdings
AUM
$1.5B
1-Year Est. Return
197.64%
This Fund
S&P 500
1 Year Est. Return
+197.64%
AUM
$1.5B
AUM Growth
+$488M
(+48%)
Holding
80
Top Buys
| 1 | +$46.6M | |
| 2 | +$28M | |
| 3 | +$27.9M | |
| 4 |
Immunovant
IMVT
|
+$24.5M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$20.6M |
Top Sells
| 1 | +$57M | |
| 2 | +$47.5M | |
| 3 | +$21.8M | |
| 4 |
Verastem
VSTM
|
+$20.9M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$19.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$19.7B
| $159M | 10.62% |
2,000,000
+250,000
|
|
||
2
Praxis Precision Medicines
PRAX
$9.34B
| $111M | 7.37% |
375,000
+250,000
|
|
||
3
IDEAYA Biosciences
IDYA
$2.83B
| $108M | 7.2% |
3,125,000
+875,000
|
|
||
4
Olema Pharmaceuticals
OLMA
$1.94B
| $80.2M | 5.35% |
3,208,875
|
|
||
|
CDTX
5
DELISTED
Cidara Therapeutics
CDTX
| $68.5M | 4.56% |
310,000
-65,000
|
|
||
|
ABVX
6
Abivax
ABVX
$9.59B
| $53.9M | 3.59% |
400,000
-15,000
|
|
||
7
Erasca
ERAS
$4.23B
| $48.4M | 3.22% |
13,000,000
-2,150,000
|
|
||
8
Ocular Therapeutix
OCUL
$1.95B
| $42.5M | 2.83% |
3,500,000
+250,000
|
|
||
9
Structure Therapeutics
GPCR
$4.45B
| $41.7M | 2.78% |
600,000
-250,000
|
|
||
10
Disc Medicine
IRON
$2.51B
| $40.5M | 2.7% |
510,000
+60,000
|
|
||
|
MAZE
11
Maze Therapeutics
MAZE
$2.19B
| $39.4M | 2.62% |
950,000
-277,300
|
|
||
12
Tango Therapeutics
TNGX
$1.5B
| $37.2M | 2.48% |
4,200,000
+3,250,000
|
|
||
|
RNAM
13
Avidity Biosciences
RNAM
$11.2B
| $36.1M | 2.4% |
500,000
-100,000
|
|
||
14
Biogen
BIIB
$28.2B
| $35.2M | 2.35% |
200,000
+100,000
|
|
||
|
15
Immunovant
IMVT
$5.64B
| $35M | 2.33% |
1,375,000
+1,100,000
|
|
||
16
Jazz Pharmaceuticals
JAZZ
$11.7B
| $34M | 2.27% |
200,000
|
|
||
17
Terns Pharmaceuticals
TERN
$4.58B
| $30.3M | 2.02% |
+750,000
|
|
||
18
Vaxcyte
PCVX
$8.86B
| $30M | 2% |
650,000
+25,000
|
|
||
19
Immunocore
IMCR
$1.64B
| $29.5M | 1.97% |
850,000
|
|
||
|
LBRX
20
LB Pharmaceuticals
LBRX
$607M
| $26.7M | 1.78% |
1,200,000
+70,000
|
|
||
21
Dyne Therapeutics
DYN
$2.57B
| $24.4M | 1.63% |
1,250,000
-1,150,000
|
|
||
22
Design Therapeutics
DSGN
$595M
| $23.4M | 1.56% |
2,500,000
-1,155,000
|
|
||
|
23
MoonLake Immunotherapeutics
MLTX
$1.24B
| $23.1M | 1.54% |
+1,750,000
|
|
||
24
Acadia Pharmaceuticals
ACAD
$4.16B
| $22.7M | 1.51% |
+850,000
|
|
||
25
Rhythm Pharmaceuticals
RYTM
$6.19B
| $20.3M | 1.36% |
190,000
-10,000
|
|